Skip to main content
Top
Published in: BMC Medicine 1/2017

Open Access 01-12-2017 | Research article

The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases

Authors: Sébastien Cortaredona, Bruno Ventelou

Published in: BMC Medicine | Issue 1/2017

Login to get access

Abstract

Background

The literature offers competing estimates of disease costs, with each study having its own data and methods. In 2007, the Dutch Center for Public Health Forecasting of the National Institute for Public Health and the Environment provided guidelines that can be used to set up cost-of-illness (COI) studies, emphasising that most COI analyses have trouble accounting for comorbidity in their cost estimations. When a patient has more than one chronic condition, the conditions may interact such that the patient’s healthcare costs are greater than the sum of the costs for the individual diseases. The main objective of this work was to estimate the costs of 10 non-communicable diseases when their co-occurrence is acknowledged and properly assessed.

Methods

The French Echantillon Généraliste de Bénéficiaires (EGB) database was used to assign all healthcare expenses for a representative sample of the population covered by the National Health Insurance. COIs were estimated in a bottom-up approach, through regressions on individuals’ healthcare expenditure. Two-way interactions between the 10 chronic disease variables were included in the expenditure model to account for possible effect modification in the presence of comorbidity(ies).

Results

The costs of the 10 selected chronic diseases were substantially higher for individuals with comorbidity, demonstrating the pattern of super-additive costs in cases of diseases interaction. For instance, the cost associated with diabetes for people without comorbidity was estimated at 1776 €, whereas this was 2634 € for people with heart disease as a comorbidity. Overall, we detected 41 cases of super-additivity over 45 possible comorbidities. When simulating a preventive action on diabetes, our results showed that significant monetary savings could be achieved not only for diabetes itself, but also for the chronic diseases frequently associated with diabetes.

Conclusions

When comorbidity exists and where super-additivity is involved, a given preventive policy leads to greater monetary savings than the costs associated with the single diagnosis, meaning that the returns from the action are generally underestimated.
Appendix
Available only for authorised users
Literature
2.
go back to reference Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy Amst Neth. 2006;77:51–63.CrossRef Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy Amst Neth. 2006;77:51–63.CrossRef
3.
go back to reference Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics. 2001;19:207–13.CrossRefPubMed Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics. 2001;19:207–13.CrossRefPubMed
4.
go back to reference Liu JLY, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart Br Card Soc. 2002;88:597–603.CrossRef Liu JLY, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart Br Card Soc. 2002;88:597–603.CrossRef
5.
go back to reference Hogan P, Dall T, Nikolov P, American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917–32.CrossRefPubMed Hogan P, Dall T, Nikolov P, American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917–32.CrossRefPubMed
6.
go back to reference Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications, and its comorbidities. Prev Med. 1999;29:173–86.CrossRefPubMed Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications, and its comorbidities. Prev Med. 1999;29:173–86.CrossRefPubMed
7.
go back to reference Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff. 2003;Suppl Web Exclusives:W3-219–26. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff. 2003;Suppl Web Exclusives:W3-219–26.
10.
go back to reference Dieleman JL, Baral R, Johnson E, Bulchis A, Birger M, Bui AL, et al. Adjusting health spending for the presence of comorbidities: an application to United States national inpatient data. Health Econ Rev. 2017;7:30.CrossRefPubMedPubMedCentral Dieleman JL, Baral R, Johnson E, Bulchis A, Birger M, Bui AL, et al. Adjusting health spending for the presence of comorbidities: an application to United States national inpatient data. Health Econ Rev. 2017;7:30.CrossRefPubMedPubMedCentral
11.
go back to reference Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316:2627–46.CrossRefPubMedPubMedCentral Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316:2627–46.CrossRefPubMedPubMedCentral
12.
go back to reference Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58:286–90.CrossRefPubMed Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58:286–90.CrossRefPubMed
14.
go back to reference Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–223.CrossRefPubMed Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–223.CrossRefPubMed
15.
go back to reference Stock SAK, Redaelli M, Wendland G, Civello D, Lauterbach KW. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med J Br Diabet Assoc. 2006;23:299–305.CrossRef Stock SAK, Redaelli M, Wendland G, Civello D, Lauterbach KW. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med J Br Diabet Assoc. 2006;23:299–305.CrossRef
16.
go back to reference Johnsen SP, Pedersen L, Friis S, Blot WJ, McLaughlin JK, Olsen JH, et al. Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case–control study. Stroke J Cereb Circ. 2003;34:387–91.CrossRef Johnsen SP, Pedersen L, Friis S, Blot WJ, McLaughlin JK, Olsen JH, et al. Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case–control study. Stroke J Cereb Circ. 2003;34:387–91.CrossRef
17.
go back to reference Huber CA, Szucs TD, Rapold R, Reich O. Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications. BMC Public Health. 2013;13:1030.CrossRefPubMedPubMedCentral Huber CA, Szucs TD, Rapold R, Reich O. Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications. BMC Public Health. 2013;13:1030.CrossRefPubMedPubMedCentral
18.
go back to reference Romon I, Rey G, Mandereau-Bruno L, Weill A, Jougla E, Eschwège E, et al. The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes--the 2001–2006 ENTRED cohort. Diabet Med J Br Diabet Assoc. 2014;31:946–53.CrossRef Romon I, Rey G, Mandereau-Bruno L, Weill A, Jougla E, Eschwège E, et al. The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes--the 2001–2006 ENTRED cohort. Diabet Med J Br Diabet Assoc. 2014;31:946–53.CrossRef
22.
go back to reference Bilger M, Finkelstein EA, Kruger E, Tate DF, Linnan LA. The effect of weight loss on health, productivity, and medical expenditures among overweight employees. Med Care. 2013;51:471–7.CrossRefPubMedPubMedCentral Bilger M, Finkelstein EA, Kruger E, Tate DF, Linnan LA. The effect of weight loss on health, productivity, and medical expenditures among overweight employees. Med Care. 2013;51:471–7.CrossRefPubMedPubMedCentral
23.
go back to reference Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77:251–77.PubMed Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77:251–77.PubMed
24.
go back to reference Finkelstein EA, DiBonaventura daCosta M, Burgess SM, Hale BC. The costs of obesity in the workplace. J Occup Environ Med Am Coll Occup Environ Med. 2010;52:971–6.CrossRef Finkelstein EA, DiBonaventura daCosta M, Burgess SM, Hale BC. The costs of obesity in the workplace. J Occup Environ Med Am Coll Occup Environ Med. 2010;52:971–6.CrossRef
25.
go back to reference Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28:w822–31.CrossRef Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28:w822–31.CrossRef
26.
go back to reference Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ. 2004;23:525–42.CrossRefPubMed Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ. 2004;23:525–42.CrossRefPubMed
27.
go back to reference Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125–44.CrossRefPubMed Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125–44.CrossRefPubMed
28.
go back to reference Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897–916.CrossRefPubMed Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897–916.CrossRefPubMed
29.
go back to reference Malehi AS, Pourmotahari F, Angali KA. Statistical models for the analysis of skewed healthcare cost data: a simulation study. Health Econ Rev. 2015;5:11.CrossRefPubMedPubMedCentral Malehi AS, Pourmotahari F, Angali KA. Statistical models for the analysis of skewed healthcare cost data: a simulation study. Health Econ Rev. 2015;5:11.CrossRefPubMedPubMedCentral
31.
go back to reference Honeycutt AA, Segel JE, Hoerger TJ, Finkelstein EA. Comparing cost-of-illness estimates from alternative approaches: an application to diabetes. Health Serv Res. 2009;44:303–20.CrossRefPubMedPubMedCentral Honeycutt AA, Segel JE, Hoerger TJ, Finkelstein EA. Comparing cost-of-illness estimates from alternative approaches: an application to diabetes. Health Serv Res. 2009;44:303–20.CrossRefPubMedPubMedCentral
32.
go back to reference Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247–81.CrossRefPubMed Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247–81.CrossRefPubMed
33.
go back to reference Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Adjusting for comorbidities in cost of illness studies. J Med Econ. 2015;18:12–28.CrossRefPubMed Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Adjusting for comorbidities in cost of illness studies. J Med Econ. 2015;18:12–28.CrossRefPubMed
34.
go back to reference Nay O, Béjean S, Benamouzig D, Bergeron H, Castel P, Ventelou B. Achieving universal health coverage in France: policy reforms and the challenge of inequalities. Lancet. 2016;387:2236–49.CrossRefPubMed Nay O, Béjean S, Benamouzig D, Bergeron H, Castel P, Ventelou B. Achieving universal health coverage in France: policy reforms and the challenge of inequalities. Lancet. 2016;387:2236–49.CrossRefPubMed
36.
go back to reference Ricordeau P, Weill A, Vallier N, Bourrel R, Schwartz D, Guilhot J, et al. The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000?*. Diabetes Metab. 2003;29:497–504.CrossRefPubMed Ricordeau P, Weill A, Vallier N, Bourrel R, Schwartz D, Guilhot J, et al. The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000?*. Diabetes Metab. 2003;29:497–504.CrossRefPubMed
39.
go back to reference Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165–74.CrossRefPubMed Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165–74.CrossRefPubMed
Metadata
Title
The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases
Authors
Sébastien Cortaredona
Bruno Ventelou
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2017
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-017-0978-2

Other articles of this Issue 1/2017

BMC Medicine 1/2017 Go to the issue